Education
About Us
Working with TipRanks
Follow Us
Repro-Med Systems, Inc. (KRMD)
:KRMD
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: -34.76%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, international expansion success, and progress in novel therapies, contributing to a positive outlook. However, there are challenges in the novel therapies segment's revenue variability and external pressures like tariffs and supply chain issues, which need monitoring.Company Guidance
During the call, KORU Medical Systems provided guidance for 2025, projecting net revenues between $38 million and $39 million, which represents growth of 13% to 16%. The company expects its full-year gross margin to be between 61% and 63%, maintaining stability despite potential one-time costs associated with manufacturing ramp-up for new consumables. KORU also anticipates being operational cash flow positive for the full year 2025. The Chief Financial Officer, Tom Adams, outlined that the growth assumptions include domestic revenue growth of 10% to 15% and international growth of over 20%, with $2 million to $3 million expected from pharma services and clinical trials. Additionally, the company plans to launch new products, including a next-generation SCIg pump and consumables, which they anticipate will drive further growth and support their strategic goal to become a global leader in large-volume subcutaneous drug delivery.Record Revenue Growth
Fourth quarter revenues grew 23%, and full-year revenues totaled $33.6 million, representing 18% growth with double-digit increases across all business segments.
International Expansion Success
International revenues grew 32% for the full year and 14% in the quarter. New geographic entries in the Middle East, North Africa, and Eastern Europe contributed to this growth.
Novel Therapies Progress
Four new collaborations were added to the pipeline in 2024, with two more announced in the first two months of 2025. The total collaboration count is now 15.
Increased Gross Margins
Full-year gross margins improved by 480 basis points to 63.4%, driven by manufacturing efficiencies and favorable customer sales.
Positive Cash Flow
The year ended with a cash balance of $9.6 million, surpassing expectations, and achieved positive cash flows in the fourth quarter.
2025 Guidance
Net revenues are expected between $38 million and $39 million, with a growth rate of 13% to 16% and a full-year gross margin between 61% and 63%.
---
KRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $3.28 | $2.70 | -17.68% |
| Nov 13, 2024 | $3.20 | $3.08 | -3.75% |
| Aug 07, 2024 | $2.13 | $2.48 | +16.43% |
| May 01, 2024 | $2.25 | $2.38 | +5.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Repro-Med Systems, Inc. (KRMD) report earnings?
Repro-Med Systems, Inc. (KRMD) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Repro-Med Systems, Inc. (KRMD) earnings time?
Repro-Med Systems, Inc. (KRMD) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KRMD EPS forecast?
KRMD EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---